In December 2023, the U.S. Food and Drug Administration approved the first medicine built on CRISPR gene-editing technology. The decision did more than clear a single treatment. It established that a therapy which rewrites a patient’s DNA could move through the same regulatory pathway used for conventional drugs, and it signaled to investors, hospitals and biotechnology firms that a long-promised field had reached the market.

In the roughly two and a half years since, the number of human gene-editing trials has climbed into the hundreds, a cluster of publicly traded companies has organized its business around the technology, and large pharmaceutical firms have begun acquiring the smaller developers. At the same time, the legal and ethical guardrails that separate treating disease from re-engineering human traits have largely held. This report examines what the FDA actually opened, which public companies are positioned to benefit, and what safeguards exist to limit misuse.

Background: What the FDA Approved

Gene editing is a set of laboratory tools that allow scientists to make targeted changes to the DNA inside living cells. The best known is CRISPR, a system that can locate a specific sequence in the genome and alter it. In simple terms, it functions like a find-and-replace tool for genetic code.

The therapy at the center of the shift is Casgevy, developed jointly by Vertex Pharmaceuticals and CRISPR Therapeutics. The United Kingdom’s medicines regulator authorized it for transfusion-dependent beta thalassemia in November 2023, and the FDA approved it for sickle cell disease on December 8, 2023. Both are inherited blood disorders. The treatment works by removing a patient’s own stem cells, editing them outside the body and returning them so they produce healthy hemoglobin.

Crucially, Casgevy is a somatic therapy. It edits the cells of a single patient and the changes are not passed to that person’s children. That distinction — somatic versus germline, or heritable — is the line around which nearly all of the field’s rules are organized.

How the Regulatory Pathway Works

The FDA regulates gene-editing treatments as biological products. A developer must obtain an Investigational New Drug authorization before testing in humans, run clinical trials, and then file for approval, after which the agency conducts post-market surveillance. This is the same multi-stage structure applied to earlier gene therapies.

In January 2024, shortly after the Casgevy decision, the FDA issued final guidance to help companies seek approval for products that use somatic genome editing, and the framework supports an accelerated approval pathway for qualifying therapies. The agency has also paired this with newer, non-binding recommendations to guide developers. The practical effect is a clearer, faster route to market for treatments that edit cells inside the body or outside it.

The European Medicines Agency has moved in parallel, having approved Casgevy and begun developing general standards. Regulatory approaches differ by country: some jurisdictions permit faster approval on a narrower showing of safety and efficacy, which is part of why governance experts watch for companies relocating research to wherever oversight is lightest.

The Public Companies Positioned to Capitalize

A defined group of publicly traded firms sits at the center of the commercial activity. Most are clinical-stage and not yet profitable, and their share prices move sharply on trial results.

• CRISPR Therapeutics (Nasdaq: CRSP) — co-developer of Casgevy with Vertex, and the highest-profile pure-play name in the sector.
• Intellia Therapeutics (Nasdaq: NTLA) — a leader in editing genes inside the body, with programs in hereditary angioedema and transthyretin amyloidosis; partnered with Regeneron.
• Beam Therapeutics (Nasdaq: BEAM) — focused on base editing, a more precise next-generation technique.
• Prime Medicine (Nasdaq: PRME) — built around prime editing; the company says its platform could potentially address roughly 90 percent of known disease-causing genetic variants.
• Editas Medicine (Nasdaq: EDIT) — advancing in vivo candidates with regulatory filings planned for 2026.
• Caribou Biosciences (Nasdaq: CRBU) — developing CRISPR-based cell therapies.
• Vertex Pharmaceuticals (Nasdaq: VRTX) — commercializes Casgevy and is among the few profitable companies with direct exposure.

Consolidation has begun. On July 25, 2025, Eli Lilly (NYSE: LLY) completed its acquisition of Verve Therapeutics, a developer of one-time gene-editing treatments for cardiovascular disease, removing Verve from public markets and signaling that established pharmaceutical companies intend to buy their way into the field rather than build from scratch.

The clinical pipeline behind these firms is substantial. As of early 2025, industry trackers counted roughly 250 gene-editing trials, with more than 150 active, spanning blood disorders, high cholesterol, hereditary blindness, cancers and autoimmune conditions. A landmark 2025 case saw a personalized CRISPR therapy designed, manufactured and delivered to an infant with a rare genetic disease in about six months, a collaboration involving the Innovative Genomics Institute, Children’s Hospital of Philadelphia, Penn Medicine and the Broad Institute.

Impact: Cost, Access and Market Reality

The early commercial picture is constrained. Casgevy carries a list price of about $2.2 million, and the treatment is difficult to manufacture and deliver, requiring specialized facilities. In 2025, 64 patients received it. These figures illustrate the gap between regulatory approval and broad availability: a therapy can be cleared and still reach only a small number of people because of cost and logistics.

For investors, the sector’s value sits largely in future potential rather than current revenue, which is why milestone events — a positive trial readout, an FDA decision, an acquisition — can move multiple stocks at once. The field is also sensitive to public funding, and reductions in U.S. government support for basic biomedical research in 2025 added pressure to the pipeline that feeds new therapies.

The Safeguards Against Misuse

The central concern in gene editing is not the treatment of disease but the prospect of heritable changes or enhancement — altering embryos, sperm or eggs in ways that pass to future generations, or editing traits unrelated to illness. Several overlapping mechanisms are designed to prevent that.

Federal funding limits. Since 1996, the Dickey-Wicker Amendment has barred federal money from research that creates or destroys human embryos. A separate provision blocks the National Institutes of Health from funding the genetic modification of embryos, sperm or eggs.

The germline rider. Beginning with the Consolidated Appropriations Act signed in December 2015, Congress has attached a rider to the FDA’s annual funding that prohibits the agency from even reviewing any application in which a human embryo is intentionally modified to include a heritable genetic change. Because the FDA cannot legally consider such a trial, the provision functions as the closest thing the United States has to a national ban on creating gene-edited babies. It must be renewed each year, and lawmakers have reinstated it on a bipartisan basis after brief attempts to remove it.

Enforcement precedent. The risks are not hypothetical. In 2018, the Chinese scientist He Jiankui announced he had created the world’s first gene-edited babies. He drew near-uniform international condemnation, and in late 2019 a Chinese court sentenced him to prison. The case remains the field’s defining cautionary example and accelerated calls for stricter global coordination.

International coordination. The World Health Organization’s Expert Advisory Committee published a governance framework and recommendations in 2021 and maintains a Human Genome Editing Registry to track clinical trials. Registration is currently voluntary, but the WHO states that failing to register qualifying work is a fundamental violation of the responsible stewardship of science. The National Academies of Sciences, Engineering, and Medicine has likewise concluded that heritable editing should proceed, if ever, only under strict conditions and in the absence of reasonable alternatives.

The limits of the system. These safeguards are real but uneven. Much of the U.S. framework rests on an annually renewed budget rider rather than permanent statute, the WHO registry is not mandatory, and rules vary widely between countries. A 2025 editorial in the journal Nature warned that the technology is advancing faster than governance can adapt and cautioned against regulatory arbitrage, in which researchers move to jurisdictions with the least oversight. Public opinion provides an additional brake: surveys consistently show broad acceptance of editing to treat disease but strong opposition to using it for enhancement.

Conclusion

The FDA’s 2023 approval marked the beginning of a commercial gene-editing market, and a defined set of public companies has organized to serve it, with larger firms now acquiring the pioneers. That activity has unfolded almost entirely within the boundary of somatic, disease-treating therapy. The structures meant to keep it there — federal funding limits, the annual germline rider, criminal enforcement abroad and international registries — have so far held, even as experts question whether annually renewed and largely voluntary measures can keep pace with a fast-moving technology and a profit-driven race to develop it.

Key Takeaways

• The FDA’s December 2023 approval of Casgevy, the first CRISPR therapy, established a clear regulatory pathway and effectively opened a commercial gene-editing market.
• Publicly traded leaders include CRISPR Therapeutics, Intellia, Beam, Prime Medicine, Editas, Caribou and Vertex; Eli Lilly acquired Verve Therapeutics in July 2025, signaling consolidation.
• Roughly 250 gene-editing trials were being tracked in early 2025, but high costs — Casgevy lists at about $2.2 million — limit near-term access.
• All current activity is somatic (treating one patient) rather than germline (heritable). That distinction defines the field’s legal and ethical limits.
• A congressional rider bars the FDA from reviewing heritable embryo-editing applications, functioning as a de facto U.S. ban; it is renewed annually.
• The 2019 imprisonment of He Jiankui, WHO’s governance framework and registry, and National Academies guidance form an overlapping but uneven safeguard system that experts say is straining to keep pace.

Sources

1. U.S. FDA — Casgevy approval and somatic genome editing guidance (via Cell / Molecular Therapy review) — https://www.cell.com/molecular-therapy-family/nucleic-acids/fulltext/S2162-2531(26)00030-2
2. Innovative Genomics Institute — CRISPR Clinical Trials 2025/2026 update — https://innovativegenomics.org/news/crispr-clinical-trials-2026/
3. CRISPR Medicine News — clinical trials register — https://crisprmedicinenews.com/clinical-trials/
4. Eli Lilly — completion of Verve Therapeutics acquisition — https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-verve-therapeutics-advance-one-time
5. The Motley Fool — CRISPR gene-editing companies and ETFs (2026) — https://www.fool.com/investing/stock-market/market-sectors/healthcare/genomics-stocks/crispr-etfs/
6. Science (Cohen & Adashi) — The FDA is Prohibited From Going Germline — https://www.science.org/doi/10.1126/science.aag2960
7. Science / AAAS — House restores U.S. ban on gene-edited babies — https://www.science.org/content/article/update-house-spending-panel-restores-us-ban-gene-edited-babies
8. World Health Organization — Human Genome Editing governance framework and recommendations — https://www.who.int/news/item/12-07-2021-who-issues-new-recommendations-on-human-genome-editing-for-the-advancement-of-public-health
9. Journal of Community Genetics — impact of major human genome editing reports on governance — https://link.springer.com/article/10.1007/s12687-025-00809-z
10. PubMed — Budgets versus Bans: How U.S. Law Restricts Germline Gene Editing — https://pubmed.ncbi.nlm.nih.gov/32311128/